Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESP301 in M. abscessus Pulmonary Disease (CF)
NCT05101915Phase 2Terminated
- Start
- Nov 2021
- Primary completion
- Jan 2024
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of RESP301 in Mycobacterium abscessus pulmonary disease. Started Nov 2021; status: terminated.
02
Drugs
RESP301
03
Conditions
Mycobacterium abscessus pulmonary disease
Beyond the preview
Go deeper on NCT05101915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05101915.